These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 37942226)
1. Downregulation of 15-PGDH enhances MASH-HCC development via fatty acid-induced T-cell exhaustion. Hu X; Yasuda T; Yasuda-Yosihara N; Yonemura A; Umemoto T; Nakachi Y; Yamashita K; Semba T; Arima K; Uchihara T; Nishimura A; Bu L; Fu L; Wei F; Zhang J; Tong Y; Wang H; Iwamoto K; Fukuda T; Nakagawa H; Taniguchi K; Miyamoto Y; Baba H; Ishimoto T JHEP Rep; 2023 Dec; 5(12):100892. PubMed ID: 37942226 [TBL] [Abstract][Full Text] [Related]
2. Targeting squalene epoxidase restores anti-PD-1 efficacy in metabolic dysfunction-associated steatohepatitis-induced hepatocellular carcinoma. Wen J; Zhang X; Wong CC; Zhang Y; Pan Y; Zhou Y; Cheung AH; Liu Y; Ji F; Kang X; Liu D; Yu J Gut; 2024 May; ():. PubMed ID: 38744443 [TBL] [Abstract][Full Text] [Related]
3. Regulation of 15-hydroxyprostaglandin dehydrogenase expression in hepatocellular carcinoma. Castro-Sánchez L; Agra N; Llorente Izquierdo C; Motiño O; Casado M; Boscá L; Martín-Sanz P Int J Biochem Cell Biol; 2013 Nov; 45(11):2501-11. PubMed ID: 23954207 [TBL] [Abstract][Full Text] [Related]
4. Interleukin-21 receptor signaling promotes metabolic dysfunction-associated steatohepatitis-driven hepatocellular carcinoma by inducing immunosuppressive IgA Xie Y; Huang Y; Li ZY; Jiang W; Shi NX; Lu Y; Cao G; Yin Z; Lin XJ Mol Cancer; 2024 May; 23(1):95. PubMed ID: 38720319 [TBL] [Abstract][Full Text] [Related]
5. Role of 15-hydroxyprostaglandin dehydrogenase down-regulation on the prognosis of hepatocellular carcinoma. Yang JE; Park E; Lee HJ; Kang HJ; Kim KM; Yu E; Lee D; Shim JH; Lim YS; Lee HC; Chung YH; Lee YS Clin Mol Hepatol; 2014 Mar; 20(1):28-37. PubMed ID: 24757656 [TBL] [Abstract][Full Text] [Related]
6. 15-PGDH inhibits hepatocellular carcinoma growth through 15-keto-PGE2/PPARγ-mediated activation of p21WAF1/Cip1. Lu D; Han C; Wu T Oncogene; 2014 Feb; 33(9):1101-12. PubMed ID: 23542179 [TBL] [Abstract][Full Text] [Related]
7. Τ cell-mediated adaptive immunity in the transition from metabolic dysfunction-associated steatohepatitis to hepatocellular carcinoma. Papadopoulos G; Giannousi E; Avdi AP; Velliou RI; Nikolakopoulou P; Chatzigeorgiou A Front Cell Dev Biol; 2024; 12():1343806. PubMed ID: 38774646 [TBL] [Abstract][Full Text] [Related]
8. Elevated expression of LCN13 through FXR activation ameliorates hepatocellular lipid accumulation and inflammation. Qin X; Tan Y; Ren W; Zhou W; Niu R; Liang L; Li J; Cao K; Wei G; Zhu X; Huang M Int Immunopharmacol; 2024 Apr; 131():111812. PubMed ID: 38493698 [TBL] [Abstract][Full Text] [Related]
9. 15-hydroxyprostaglandin dehydrogenase (15-PGDH) prevents lipopolysaccharide (LPS)-induced acute liver injury. Yao L; Chen W; Song K; Han C; Gandhi CR; Lim K; Wu T PLoS One; 2017; 12(4):e0176106. PubMed ID: 28423012 [TBL] [Abstract][Full Text] [Related]
10. From MASH to HCC: the role of Gas6/TAM receptors. Apostolo D; Ferreira LL; Vincenzi F; Vercellino N; Minisini R; Latini F; Ferrari B; Burlone ME; Pirisi M; Bellan M Front Immunol; 2024; 15():1332818. PubMed ID: 38298195 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of 15-PGDH causes Kras-driven tumor expansion through prostaglandin E2-ALDH1 signaling in the pancreas. Arima K; Ohmuraya M; Miyake K; Koiwa M; Uchihara T; Izumi D; Gao F; Yonemura A; Bu L; Okabe H; Imai K; Hashimoto D; Baba Y; Chikamoto A; Yamashita YI; Furukawa T; Araki K; Baba H; Ishimoto T Oncogene; 2019 Feb; 38(8):1211-1224. PubMed ID: 30250298 [TBL] [Abstract][Full Text] [Related]
12. Tumor microenvironmental 15-PGDH depletion promotes fibrotic tumor formation and angiogenesis in pancreatic cancer. Bu L; Yonemura A; Yasuda-Yoshihara N; Uchihara T; Ismagulov G; Takasugi S; Yasuda T; Okamoto Y; Kitamura F; Akiyama T; Arima K; Itoyama R; Zhang J; Fu L; Hu X; Wei F; Arima Y; Moroishi T; Nishiyama K; Sheng G; Mukunoki T; Otani J; Baba H; Ishimoto T Cancer Sci; 2022 Oct; 113(10):3579-3592. PubMed ID: 35848891 [TBL] [Abstract][Full Text] [Related]
13. State of CD8 Zhong X; Lv M; Ma M; Huang Q; Hu R; Li J; Yi J; Sun J; Zhou X Biomed Pharmacother; 2023 Sep; 165():115131. PubMed ID: 37429231 [TBL] [Abstract][Full Text] [Related]
15. Downregulation of 15-hydroxyprostaglandin dehydrogenase by interleukin-1β from activated macrophages leads to poor prognosis in pancreatic cancer. Arima K; Komohara Y; Bu L; Tsukamoto M; Itoyama R; Miyake K; Uchihara T; Ogata Y; Nakagawa S; Okabe H; Imai K; Hashimoto D; Chikamoto A; Yamashita YI; Baba H; Ishimoto T Cancer Sci; 2018 Feb; 109(2):462-470. PubMed ID: 29224225 [TBL] [Abstract][Full Text] [Related]
16. Prostaglandin E Kim HB; Kim M; Park YS; Park I; Kim T; Yang SY; Cho CJ; Hwang D; Jung JH; Markowitz SD; Hwang SW; Yang SK; Lim DS; Myung SJ Gastroenterology; 2017 Feb; 152(3):616-630. PubMed ID: 27864128 [TBL] [Abstract][Full Text] [Related]
18. The XOR-IDH3α axis controls macrophage polarization in hepatocellular carcinoma. Lu Y; Sun Q; Guan Q; Zhang Z; He Q; He J; Ji Z; Tian W; Xu X; Liu Y; Yin Y; Zheng C; Lian S; Xu B; Wang P; Jiang R; Sun B J Hepatol; 2023 Nov; 79(5):1172-1184. PubMed ID: 37473847 [TBL] [Abstract][Full Text] [Related]
19. Regional differences in prostaglandin E₂ metabolism in human colorectal cancer liver metastases. Young AL; Chalmers CR; Hawcroft G; Perry SL; Treanor D; Toogood GJ; Jones PF; Hull MA BMC Cancer; 2013 Feb; 13():92. PubMed ID: 23442768 [TBL] [Abstract][Full Text] [Related]
20. Metabolic Dysfunction-Associated Steatohepatitis and Progression to Hepatocellular Carcinoma: A Literature Review. Ghazanfar H; Javed N; Qasim A; Zacharia GS; Ghazanfar A; Jyala A; Shehi E; Patel H Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539547 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]